Last reviewed · How we verify
NCT04799613
Provocation of Freezing of Gait in Parkinson's Disease
NA trial testing walking speed in Parkinson Disease in 20 participants. Completed in 15 June 2022.
15 June 2022
Quick facts
| Lead sponsor | University of Toronto |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 20 |
| Start date | 15 March 2021 |
| Primary completion | 15 June 2022 |
| Estimated completion | 15 June 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- walking speed
- visual loading
- dual task
- best side reduction
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Freezing of Gait — all drugs for Freezing of Gait →
Sponsor
University of Toronto
Who can join
Adults 20 to 85, any sex, with Parkinson Disease or Freezing of Gait. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sample Size N= 10 Parkinson's disease patients with self-reported freezing of gait and 10 without self-reported freezing of gait (in total, 20 Parkinson's disease patients) Accrual Period Single visit for 2 hours Study Design This is a cross-sectional study with an intervention to provoke freezing of gait using split-belt treadmill in Parkinson's disease patients with a randomized cross-over design. After baseline evaluation (a), interventions to induce freezing of gait will be performed in a randomized order to avoid a practice/fatigue effect in the following conditions using combination of 4 interventions: walking speed (fast walking vs. natural walking), visual loading (passing through narrow pathway), cognitive loading (dual task), and asymmetry (best side reduction). 1. Natural and fast walking with self-paced mode to access gait parameters and decide the speed for evaluation (3 mins X2) remaining assessment will be randomized and performed on the treadmill: 2. Natural and fast walking passing through narrow pathway (2 mins X2) 3. Natural and fast walking with dual task (2 mins X2) 4. Natural and fast walking passing through narrow pathway and during cognitive dual task (2 mins X2) 5. Natural and fast walking reducing the best side (2 mins X2) 6. Natural and fast walking reducing the best side passing through narrow pathway (2 mins X2) 7. Natural and fast walking reducing the best side with cognitive dual task (2 mins X2) 8. Natural and fast walking reducing the best side passing through narrow pathway and during cognitive dual task (2 mins X2) * Conditions b-h will be carried out on a split-belt treadmill (Grail systems®, by Motek, Netherlands). * (b-i) freezing of gait episodes will be identified with synchronized videorecordings (screening done by two independent observers). Episodes identified by both observers will be confirmed and measured by comparing the relative height of metatarsal and heel markers of each foot, in keeping with a previous study evaluating freezing of gait episode on a treadmill. Study Duration 1. (Baselines evaluation) Enrolment and assessment (Montreal cognitive assessment, Movement Disorders Society-unified Parkinson's disease rating scale part 2, 3 and 4, Activities-Specific Balance Confidence Scale, Parkinson's disease questionnaire-39, and New freezing of gait questionnaire) 2. (a) Formal gait analysis using split-belt treadmill (Grail systems®, by Motek, Netherlands) will be done for baseline assessment (normal walking) and to test patient's ability for fast walking (25% of the normal speed). 3. (b-h) Provocation of freezing of gait at split-belt treadmill (Grail systems®, by Motek, Netherlands) with natural and fast walking with/without additional loading or interventions on the asymmetry Total time= 2 hours Study Intervention Freezing of gait will be provoked based on the situations combined among 4 conditions; (1) interventions on asymmetry, (2) cognitive dual task, (3) visual loading - passing through narrow pathway, and (4) walking speed at a split-belt treadmill. * Fast walking will be defined as walking 25% faster than the normal comfortable walking. Subjects who cannot reach this speed, will be asked to walk at their safest maximum speed. * Passing narrow pathway will be done by walking in a "rope bridge" scene in virtual reality (VR). * Dual cognitive task will be carried out with serial subtraction prompted on the screen in VR. * Best side reduction will be defined as 25% slower speed on the best side based on the speed during the initial natural walking with tied configuration setting based on a previous study.3 * Condition b-h will be randomized.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04799613
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other University of Toronto trials
Trials by the same sponsor.
- NCT07184255 — Animated Video Education for Retinal Surgery · NA · not yet recruiting
- NCT07259434 — Time Restricted Eating in Survivors Trial 2.0 · NA · not yet recruiting
- NCT07486050 — The Impact of Social Worker Referrals on Diabetes and Loneliness · NA · active not recruiting
- NCT07268729 — Investigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders · not yet recruiting
- NCT07317921 — Validating IAAO for Muscle Outcomes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04799613 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Toronto
- Last refreshed: 18 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799613.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing